PHP
STOK icon

Parkman Healthcare Partners’s Stoke Therapeutics STOK Stock Holding History

Parkman Healthcare Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Buy
355,443
+18,924
+6% +$607K 1.19% 33
2026
Q1 		$11M Sell
336,519
-93,636
-22% -$3.07M 1.13% 30
2025
Q4 		$13.7M Buy
430,155
+180,155
+72% +$5.42M 1.3% 24
2025
Q3 		$5.88M Buy
+250,000
New +$4.28M 0.61% 59

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parkman Healthcare Partners's STOK Position: Q2 2026 in Review

Parkman Healthcare Partners increased its Stoke Therapeutics (STOK) stake by 5.6% in Q2 2026, buying an estimated $607K and bringing the position to 355,443 shares worth $11.6M. The position accounts for 1.19% of the portfolio, ranked #33.

Parkman Healthcare Partners first reported a position in STOK in Q3 2025 and has held it in 4 quarters since. The position peaked at $13.7M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Parkman Healthcare Partners held 355,443 shares of Stoke Therapeutics worth $11.6M as of Q2 2026.
  • Parkman Healthcare Partners bought 18,924 Stoke Therapeutics shares in Q2 2026, an estimated $607K.
  • Stoke Therapeutics made up 1.19% of Parkman Healthcare Partners's portfolio in Q2 2026, its #33 holding.
  • Parkman Healthcare Partners first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Parkman Healthcare Partners's Stoke Therapeutics position peaked at $13.7M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.